

# company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 29 August 2022** – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Under the programme initiated 3 August 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 August 2022 to 31 October 2022.

Since the announcement 22 August 2022, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
<b>Accumulated, last announcement</b>	<b>1,085,000</b>		<b>836,417,968</b>
22 August 2022	90,000	784.72	70,624,781
23 August 2022	85,000	795.46	67,613,823
24 August 2022	85,000	803.19	68,271,084
25 August 2022	85,000	817.83	69,515,956
26 August 2022	85,000	820.06	69,705,522
<b>Accumulated under the programme</b>	<b>1,515,000</b>		<b>1,182,149,134</b>

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](http://novonordisk.com).

With the transactions stated above, Novo Nordisk owns a total of 19,133,211 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 26 August 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 17,422,432 B shares at an average share price of DKK 768.20 per B share equal to a transaction value of DKK 13,383,917,995

*Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#) and [YouTube](#).*

## Further information

### Media:

Ambre Brown Morley

+45 3079 9289

[abmo@novonordisk.com](mailto:abmo@novonordisk.com)

Natalia Salomao Abrahao (US)

+1 848 304 1027

[niaa@novonordisk.com](mailto:niaa@novonordisk.com)

### Investors:

Daniel Muusmann Bohsen

+45 3075 2175

[dabo@novonordisk.com](mailto:dabo@novonordisk.com)

Jacob Martin Wiborg Rode

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

David Heiberg Landsted

+45 3077 6915

[dhel@novonordisk.com](mailto:dhel@novonordisk.com)

Mark Joseph Root (US)

+1 848 213 3219

[mjhr@novonordisk.com](mailto:mjhr@novonordisk.com)